Stay updated with breaking news from Thomas Theuringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
QIAGEN leverages QuantiFERON-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also
Selection comes as part of an expansion in the DAX (Deutscher Aktienindex) to the 40 largest companies based on market capitalizationQIAGEN to join the DAX on September 20, 2021, the effective date for changes in index compositionQIAGEN to remain in TecDAX comprised of the 30 largest German technology sector compani...
(0) The therascreen KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS TM (sotorasib) from Amgen KRAS G12C mutation in NSCLC Test will be available under QIAGEN's Day One Lab Readiness program QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit ( therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identificatio...
QIAGEN N.V.: QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Mirati's investigational selective KRAS G12C inhibitor Program adds to QIAGEN's strong position in KRAS companion diagnostic testing in NSCLC QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers t...
(2) U.S. authorization gives healthcare professionals access to portable rapid testing device that can monitor immune status in relation to COVID-19 Test based on QIAGEN partner Ellume's proprietary eHub technology and helps ease testing shortfalls by using automation and providing easy-to-read results eHub digital device can handle eight tests at once, all working independently of each other, can process up to 32 samples per hour, can eventually be used simultaneously with the antigen test QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use ...